Clinical trial NCT03418675 - References

Borderline Personality Disorder — Brexpiprazole in Borderline Personality Disorder

Citation(s)

•   Barratt E: Anxiety and impulsiveness related to psychomotor efficiency
  Percept Mot Skills 1959; 9:191-198
•   Black DW, Blum N, Pfohl B, Hale N
  Suicidal behavior in borderline personality disorder: prevalence, risk factors, prediction, and prevention. J Pers Disord. 2004 Jun;18(3):226-39. Review.
•   Blum N, St John D, Pfohl B, Stuart S, McCormick B, Allen J, Arndt S, Black DW
  Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. Am J Psychiatry. 2008 Apr;165(4):468-78. doi: 10.1176/appi.ajp.2007.07071079. Epub 2008 Feb 15. Erratum in: Am J Psychiatry. 2008 Jun;165(6):777.
•   Bogenschutz MP, George Nurnberg H
  Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004 Jan;65(1):104-9.
•   Crandell LE, Patrick MP, Hobson RP
  'Still-face' interactions between mothers with borderline personality disorder and their 2-month-old infants. Br J Psychiatry. 2003 Sep;183:239-47.
•   Derogatis LR: SCL-90-R Administration, Scoring, and Procedures Manual II
  Towson, Md, Clinical Psychometric Research, 1983
•   Ferreri MM, Loze JY, Rouillon F, Limosin F
  Clozapine treatment of a borderline personality disorder with severe self-mutilating behaviours. Eur Psychiatry. 2004 May;19(3):177-8. Erratum in: Eur Psychiatry. 2004 Sep;19(6):393. Ferrerri, MM [corrected to Ferreri, M].
•   Flewett T, Bradley P, Redvers A
  Management of borderline personality disorder. Br J Psychiatry. 2003 Jul;183:78-9.
•   Frankenburg FR, Zanarini MC
  The association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. J Clin Psychiatry. 2004 Dec;65(12):1660-5.
•   Friedel RO
  Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology. 2004 Jun;29(6):1029-39. Review.
•   Frisch MB, Cornell J, Villaneuva M (1993)
  Clinical validation of the Quality of Life Inventory: a measure of life satisfaction for use in treatment planning and outcome assessment. Psychol Assess. 4:92-101.
•   Gunderson J: Borderline Personality Disorder, 2nd ed
  Washington, DC, American Psychiatric Press, 2000
•   HAMILTON M
  A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62.
•   HAMILTON M
  The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5.
•   Hansenne M, Pitchot W, Pinto E, Reggers J, Scantamburlo G, Fuchs S, Pirard S, Ansseau M
  5-HT1A dysfunction in borderline personality disorder. Psychol Med. 2002 Jul;32(5):935-41.
•   Kay SR, Wolkenfeld F, Murrill LM
  Profiles of aggression among psychiatric patients. I. Nature and prevalence. J Nerv Ment Dis. 1988 Sep;176(9):539-46.
•   Leucht S, Wahlbeck K, Hamann J, Kissling W
  New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003 May 10;361(9369):1581-9. Review.
•   Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM
  Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010 Jan;196(1):4-12. doi: 10.1192/bjp.bp.108.062984. Review.
•   Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M
  Borderline personality disorder. Lancet. 2004 Jul 31-Aug 6;364(9432):453-61. Review.
•   Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, Korslund KE, Tutek DA, Reynolds SK, Lindenboim N
  Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry. 2006 Jul;63(7):757-66. Erratum in: Arch Gen Psychiatry. 2007 Dec;64(12):1401.
•   MacKinnon DF, Zandi PP, Gershon E, Nurnberger JI Jr, Reich T, DePaulo JR
  Rapid switching of mood in families with multiple cases of bipolar disorder. Arch Gen Psychiatry. 2003 Sep;60(9):921-8.
•   Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, Stensbøl TB, Bundgaard C, Arnt J, Kikuchi T
  Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014 Sep;350(3):605-14. doi: 10.1124/jpet.114.213819. Epub 2014 Jun 19. Erratum in: J Pharmacol Exp Ther. 2014 Dec;351(3):686-7.
•   Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbøl TB, Kikuchi T
  Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014 Sep;350(3):589-604. doi: 10.1124/jpet.114.213793. Epub 2014 Jun 19.
•   McMain SF, Guimond T, Streiner DL, Cardish RJ, Links PS
  Dialectical behavior therapy compared with general psychiatric management for borderline personality disorder: clinical outcomes and functioning over a 2-year follow-up. Am J Psychiatry. 2012 Jun;169(6):650-61. doi: 10.1176/appi.ajp.2012.11091416.
•   Nakao K, Gunderson JG, Phillips KA, Tanaka N: Functional impairment in personality disorders
  J Pers Disord 1992; 6:24-31
•   Nickel M, Leiberich P, Mitterlehner F: Atypical neuroleptics in personality disorders
  Psychodynamic Psychotherapy 2003; 2:25-32
•   Nickel M, Nickel C, Leiberich P, Mitterlehner F, Forthuber P, Tritt K, Rother W, Loew T
  [Psychosocial characteristics in persons who often change their psychotherapists]. Wien Med Wochenschr. 2004 Apr;154(7-8):163-9. German.
•   Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, Buschmann W, Rother N, Fartacek R, Egger C, Anvar J, Rother WK, Loew TH, Kaplan P
  Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006 May;163(5):833-8.
•   Nickel MK, Nickel C, Kaplan P, Lahmann C, Mühlbacher M, Tritt K, Krawczyk J, Leiberich PK, Rother WK, Loew TH
  Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005 Mar 1;57(5):495-9.
•   Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, Rother WK, Loew TH
  Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2004 Nov;65(11):1515-9.
•   Pascual JC, Oller S, Soler J, Barrachina J, Alvarez E, Pérez V
  Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services. J Clin Psychiatry. 2004 Sep;65(9):1281-2.
•   Pascual JC, Soler J, Puigdemont D, Pérez-Egea R, Tiana T, Alvarez E, Pérez V
  Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 2008 Apr;69(4):603-8.
•   Pfohl B, Blum N, St John D, McCormick B, Allen J, Black DW
  Reliability and validity of the Borderline Evaluation of Severity Over Time (BEST): a self-rated scale to measure severity and change in persons with borderline personality disorder. J Pers Disord. 2009 Jun;23(3):281-93. doi: 10.1521/pedi.2009.23.3.281.
•   Rinne T, de Kloet ER, Wouters L, Goekoop JG, de Rijk RH, van den Brink W
  Fluvoxamine reduces responsiveness of HPA axis in adult female BPD patients with a history of sustained childhood abuse. Neuropsychopharmacology. 2003 Jan;28(1):126-32.
•   Schulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q, Tanaka Y, Lin D, Deberdt W, Corya S
  Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008 Dec;193(6):485-92. doi: 10.1192/bjp.bp.107.037903.
•   Sheehan DV (1983)
  The Anxiety Disease. New York: Scribner's.
•   Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC
  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57. Review.
•   Sher L, Oquendo MA, Li S, Huang YY, Grunebaum MF, Burke AK, Malone KM, Mann JJ
  Lower CSF homovanillic acid levels in depressed patients with a history of alcoholism. Neuropsychopharmacology. 2003 Sep;28(9):1712-9. Epub 2003 Jun 25.
•   Soloff PH, George A, Nathan S, Schulz PM, Cornelius JR, Herring J, Perel JM
  Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol. 1989 Aug;9(4):238-46.
•   Verheul R, Van Den Bosch LM, Koeter MW, De Ridder MA, Stijnen T, Van Den Brink W
  Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. Br J Psychiatry. 2003 Feb;182:135-40.
•   Yen S, Shea MT, Sanislow CA, Grilo CM, Skodol AE, Gunderson JG, McGlashan TH, Zanarini MC, Morey LC
  Borderline personality disorder criteria associated with prospectively observed suicidal behavior. Am J Psychiatry. 2004 Jul;161(7):1296-8.
•   Yoon S, Jeon SW, Ko YH, Patkar AA, Masand PS, Pae CU, Han C
  Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychopharmacol. 2017 Feb;37(1):46-53. doi: 10.1097/JCP.0000000000000622. Review.
•   Young RC, Biggs JT, Ziegler VE, Meyer DA
  A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978 Nov;133:429-35.
•   Zanarini MC, Frankenburg FR, Hennen J, Silk KR
  The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Am J Psychiatry. 2003 Feb;160(2):274-83.
•   Zanarini MC, Frankenburg FR, Parachini EA
  A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004 Jul;65(7):903-7.
•   Zanarini MC, Frankenburg FR
  Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001 Nov;62(11):849-54.
•   Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, Deberdt W, Kryzhanovskaya L, Corya S
  A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011 Oct;72(10):1353-62. doi: 10.4088/JCP.08m04138yel.
•   Zanarini MC, Vujanovic AA, Parachini EA, Boulanger JL, Frankenburg FR, Hennen J
  Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers Disord. 2003 Jun;17(3):233-42. Erratum in: J Personal Disord. 2003 Aug;17(4):1 p following 369.
•   Zanarini MC, Weingeroff JL, Frankenburg FR, Fitzmaurice GM
  Development of the self-report version of the Zanarini Rating Scale for Borderline Personality Disorder. Personal Ment Health. 2015 Nov;9(4):243-9. doi: 10.1002/pmh.1302. Epub 2015 Jul 14.
•   Zanarini MC
  Update on pharmacotherapy of borderline personality disorder. Curr Psychiatry Rep. 2004 Feb;6(1):66-70. Review.

A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder.

Details for clinical trial NCT03418675